Tag: Systemic Lupus Erythematosus
Vaccinated rheumatic patients carry increased risk for COVID-19 breakthrough infections
B-cell depleting medication increases COVID-19 breakthrough infection outcome risk
COVID-19 mRNA vaccine safe and tolerable in adults with autoimmune disease
Iberdomide: an upcoming new treatment possibility in lupus erythematosus
Sequential rituximab after belimumab does not improve disease control in SLE
Lupus patients less protected by COVID-19 vaccine
Paediatric dermatology in Tunisia: common diagnoses
Systemic lupus erythematosus: increased risk of severe infection
No heightened outcome risk for rheumatic patients with COVID-19
Lupus nephritis biomarkers: moving toward an omic-driven approach
Lupus nephritis: new therapies on the horizon in 2020
Inflammatory disease as a risk factor for fractures
Hydroxychloroquine use: no indication for arrhythmias in RA and SLE patients
Children with rheumatic disease have no greater risk of a COVID-19 infection
Anifrolumab achieves rapid and durable BICLA-response
Wide variation in prescription and dosing patterns for hydroxychloroquine in SLE
Anifrolumab succeeds in second phase 3 trial in SLE
Prevention of congenital heart block may be possible with hydroxychloroquine
Depression closely related to fatigue in SLE patients
New targets and biologics for cutaneous lupus erythematosus
